Asymptomatic Hyperuricemia and Functional State of the Kidneys in Patients with Essential Arterial Hypertension and Concomitant Diabetes Mellitus Type 2



Abstract Views
467

Downloads
221

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Apr 22, 2021
Published Jun 30, 2021
10.24018/clinicmed.2021.2.3.65

Abstract viewed = 467 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Introduction: The manuscript analyzes the frequency of asymptomatic hyperuricemia in association with disturbance of glucose and lipid metabolism, inflammatory process, and kidney changes in patients with essential arterial hypertension (EAH) and concomitant diabetes mellitus type 2 (DM2).

Aim: To determine the frequency of asymptomatic hyperuricemia in patients with EAH and concomitant DM2 and their effects on the main indicators of comorbid pathology.

Materials and methods: 120 patients (51 males and 69 females), aged 45-69 years with average age being (58.2±5.7) years, were studied: 25 patients with treatment-compensated EAH, 1-2 degree, II stage (Group I); 25 patients with subcompensated DM2 (Group II) and 70 patients with treatment-compensated EAH, 1-2 degree, II stage and concomitant subcompensated DM2 (Group III). Control group consisted of 20 practically healthy volunteers - 8 (40.0%) males and 12 (60.0%) females, aged (54.7±4.9) years. Groups were randomized according to age, sex, BMI, duration of EAH and DM2.

Results and discussion: Asymptomatic hyperuricemia were observed in 36.0% of group І patients, in 24.0% of group II patients and in 46.7% of group ІІІ patients. Relevant correlations were found between uric acid level in the blood and such indicators as/for systolic blood pressure (SBP), glycated hemoglobin (HbA1C), dyslipidemia, inflammatory process, and kidney damage.

Conclusion: Asymptomatic hyperuricemia has a negative effect on the main indicators of comorbid pathology - in this case, EAH and concomitant DM2.

Keywords: asymptomatic, hyperuricemia, diabetes mellitus type 2, essential arterial hypertension, kidneys

References

  1. MOH Ukraine (2012) Adapted clinical guidelines, based on evidence “Diabetes mellitus type 2” Order No. 1118 dated 21.12.2012 Available: http://www.moz.gov.ua/docfiles/dod1118_1_2012_.pdf.
     Google Scholar
  2. Tronko MD (2014) Reference key performance indicators in endocrinological service of Ukraine for 2013. Endocrinology 19(1):40.
     Google Scholar
  3. American Diabetes Association (ADA) (2017) Standards of medical care in diabetes. Diabetes care 40(1):75-98.
     Google Scholar
  4. MOH Ukraine (2012) Guidelines and clinical protocols of medical care “Arterial hypertension” Order No. 384 dated 24.05.2012. Page 107.
     Google Scholar
  5. Trifiro G, Sultana J, Giorgianni F, Ingrasciotta Y, Buemi M, Muscianisi M, et al (2014), Chronic kidney disease requiring healthcare services: a new approach to evaluate epidemiology of renal disease. BioMed Research International DOI: http://dx.doi.org/10.1155/2014/268362.
     Google Scholar
  6. Tashchuk VK, Vasek Obeid Al' Salama Muhamed (2016) Comorbidity, cardiovascular pathology and treatment of hyperuricemia - does allopurinol prevent its development? Bukovynsky medical bulletin 20(2): 209-212.
     Google Scholar
  7. Vassalle C, Mazzone A, Sabatino L, Carpeggiani C (2016) Uric acid for cardiovascular risk: Dr. Jekyll or Mr. Hide? Diseases 4(1) DOI: 10.3390/diseases4010012.
     Google Scholar
  8. Zhdan VM, Kitura OYe, Kitura YeM, Babanina MYu, Tkachenko MV (2015) Hyperuricemia and arterial hypertension in general medical practice. Family medicine 4: 48-50.
     Google Scholar
  9. Yakymenko YL (2014) Features of arterial hypertension combined with hyperuricemia in men. Ukr. med. journal 1(99): 1-2. Available online:http://www.umj.com.ua/article/70737/osobennosti-arterialnoj-gipertenzii-pri-sochetanii-s-giperurikemiej-u-muzhchin.
     Google Scholar
  10. Mishchenko LA (2016) Hyperuricemia and arterial hypertension – is there a connection? Ukrainian cardiology journal 3: 24-29.
     Google Scholar
  11. El Ridi R, Tallima HJ (2017) Physiological functions and pathogenic potential of uric acid: a review. Adv. Res. 8(5):487-493. DOI:10.1016/j.jare.2017.03.003.
     Google Scholar
  12. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrology Dialysis Transplantation 28(9): 2221-2228. DOI: 10.1093/ndt/gft029.
     Google Scholar
  13. Jalal DI, Chonchol M, Chen W, Targher G (2013) Uric acid as a target of therapy in CKD. American Journal of Kidney Diseases 61:134–146.
     Google Scholar
  14. Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al (2015) Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. American Journal of Kidney Diseases 65:543–549.
     Google Scholar
  15. Kimura K, Hosoya T, Uchida S, et al (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. American Journal of Kidney Diseases 72: 798-810.
     Google Scholar
  16. Mallamaci CZF (2018) Uric acid in chronic kidney disease: the quest for causality continues. Nephrology Dialysis Transplantation 33(2): 193-195. DOI: 10.1093/ndt/gfx341.
     Google Scholar